Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)

S. Møller-Bisgaard; B. J. Ejbjerg; I. Eshed; K. Hørslev-Petersen; M. L. Hetland; A. G. Jurik; H. Thomsen; T. Torfing; K. Stengaard-Pedersen; P. Junker; N. S. Krogh; T. Lottenburger; T. Ellingsen; L. S. Andersen; H. Skjødt; A. J. Svendsen; U. Tarp; I. T. Hansen; J. Pødenphant; J. K. Pedersen; H. Lindegaard; Lars G.  Hanson; A. Vestergaard; D. Glinatsi; M. Østergaard

doi:10.1080/03009742.2016.1209550

Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)

S. Møller-Bisgaard, B. J. Ejbjerg, I. Eshed, K. Hørslev-Petersen, M. L. Hetland, A. G. Jurik, H. Thomsen, T. Torfing, K. Stengaard-Pedersen, P. Junker, N. S. Krogh, T. Lottenburger, T. Ellingsen, L. S. Andersen, H. Skjødt, A. J. Svendsen, U. Tarp, I. T. Hansen, J. Pødenphant, J. K. PedersenH. Lindegaard, Lars G. Hanson, A. Vestergaard, D. Glinatsi, M. Østergaard

Research output: Contribution to journal › Journal article › Research › peer-review

1 Downloads (Pure)

Abstract

Objectives: To investigate whether a treat-to-target strategy based on methotrexate (MTX) and intra-articular (IA) betamethasone suppresses magnetic resonance imaging (MRI)-determined measures of disease activity and reduces joint destruction in early rheumatoid arthritis (eRA) patients, and to investigate whether concomitant cyclosporin A (CyA) provides an additional effect.Method: In the 2-year randomized, double-blind, treat-to-target trial CIMESTRA, 160 patients with eRA (<6months) were randomized to MTX, intra-articular betamethasone and CyA, or placebo CyA. A total of 129 patients participated in the MRI substudy, and had contrast-enhanced MR images of the non-dominant hand at months 0, 6, 12, and 24. MR images were evaluated for osteitis, synovitis, tenosynovitis, bone erosion, and joint space narrowing (JSN), using validated scoring methods.Results: Significant reductions were seen at 6months in all inflammatory parameters [synovitis, mean change -1.6 (p

Original language	English
Journal	Scandinavian Journal of Rheumatology
Volume	46
Issue number	5
Pages (from-to)	335-345
ISSN	0300-9742
DOIs	https://doi.org/10.1080/03009742.2016.1209550
Publication status	Published - 2017

Access to Document

10.1080/03009742.2016.1209550

OpenUrl availability

Full text

Fingerprint

Dive into the research topics of 'Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)'. Together they form a unique fingerprint.

Cite this

Møller-Bisgaard, S., Ejbjerg, B. J., Eshed, I., Hørslev-Petersen, K., Hetland, M. L., Jurik, A. G., Thomsen, H., Torfing, T., Stengaard-Pedersen, K., Junker, P., Krogh, N. S., Lottenburger, T., Ellingsen, T., Andersen, L. S., Skjødt, H., Svendsen, A. J., Tarp, U., Hansen, I. T., Pødenphant, J., ... Østergaard, M. (2017). Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). Scandinavian Journal of Rheumatology, 46(5), 335-345. https://doi.org/10.1080/03009742.2016.1209550

Møller-Bisgaard, S. ; Ejbjerg, B. J. ; Eshed, I. et al. / Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). In: Scandinavian Journal of Rheumatology. 2017 ; Vol. 46, No. 5. pp. 335-345.

@article{97257abeb26f4c05b3f925a97b1cd649,

title = "Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)",

abstract = "Objectives: To investigate whether a treat-to-target strategy based on methotrexate (MTX) and intra-articular (IA) betamethasone suppresses magnetic resonance imaging (MRI)-determined measures of disease activity and reduces joint destruction in early rheumatoid arthritis (eRA) patients, and to investigate whether concomitant cyclosporin A (CyA) provides an additional effect.Method: In the 2-year randomized, double-blind, treat-to-target trial CIMESTRA, 160 patients with eRA (<6months) were randomized to MTX, intra-articular betamethasone and CyA, or placebo CyA. A total of 129 patients participated in the MRI substudy, and had contrast-enhanced MR images of the non-dominant hand at months 0, 6, 12, and 24. MR images were evaluated for osteitis, synovitis, tenosynovitis, bone erosion, and joint space narrowing (JSN), using validated scoring methods.Results: Significant reductions were seen at 6months in all inflammatory parameters [synovitis, mean change -1.6 (p",

author = "S. M{\o}ller-Bisgaard and Ejbjerg, {B. J.} and I. Eshed and K. H{\o}rslev-Petersen and Hetland, {M. L.} and Jurik, {A. G.} and H. Thomsen and T. Torfing and K. Stengaard-Pedersen and P. Junker and Krogh, {N. S.} and T. Lottenburger and T. Ellingsen and Andersen, {L. S.} and H. Skj{\o}dt and Svendsen, {A. J.} and U. Tarp and Hansen, {I. T.} and J. P{\o}denphant and Pedersen, {J. K.} and H. Lindegaard and Hanson, {Lars G.} and A. Vestergaard and D. Glinatsi and M. {\O}stergaard",

year = "2017",

doi = "10.1080/03009742.2016.1209550",

language = "English",

volume = "46",

pages = "335--345",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "CRC Press/Balkema",

number = "5",

}

Møller-Bisgaard, S, Ejbjerg, BJ, Eshed, I, Hørslev-Petersen, K, Hetland, ML, Jurik, AG, Thomsen, H, Torfing, T, Stengaard-Pedersen, K, Junker, P, Krogh, NS, Lottenburger, T, Ellingsen, T, Andersen, LS, Skjødt, H, Svendsen, AJ, Tarp, U, Hansen, IT, Pødenphant, J, Pedersen, JK, Lindegaard, H, Hanson, LG, Vestergaard, A, Glinatsi, D & Østergaard, M 2017, 'Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)', Scandinavian Journal of Rheumatology, vol. 46, no. 5, pp. 335-345. https://doi.org/10.1080/03009742.2016.1209550

Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). / Møller-Bisgaard, S.; Ejbjerg, B. J.; Eshed, I. et al.
In: Scandinavian Journal of Rheumatology, Vol. 46, No. 5, 2017, p. 335-345.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)

AU - Møller-Bisgaard, S.

AU - Ejbjerg, B. J.

AU - Eshed, I.

AU - Hørslev-Petersen, K.

AU - Hetland, M. L.

AU - Jurik, A. G.

AU - Thomsen, H.

AU - Torfing, T.

AU - Stengaard-Pedersen, K.

AU - Junker, P.

AU - Krogh, N. S.

AU - Lottenburger, T.

AU - Ellingsen, T.

AU - Andersen, L. S.

AU - Skjødt, H.

AU - Svendsen, A. J.

AU - Tarp, U.

AU - Hansen, I. T.

AU - Pødenphant, J.

AU - Pedersen, J. K.

AU - Lindegaard, H.

AU - Hanson, Lars G.

AU - Vestergaard, A.

AU - Glinatsi, D.

AU - Østergaard, M.

PY - 2017

Y1 - 2017

N2 - Objectives: To investigate whether a treat-to-target strategy based on methotrexate (MTX) and intra-articular (IA) betamethasone suppresses magnetic resonance imaging (MRI)-determined measures of disease activity and reduces joint destruction in early rheumatoid arthritis (eRA) patients, and to investigate whether concomitant cyclosporin A (CyA) provides an additional effect.Method: In the 2-year randomized, double-blind, treat-to-target trial CIMESTRA, 160 patients with eRA (<6months) were randomized to MTX, intra-articular betamethasone and CyA, or placebo CyA. A total of 129 patients participated in the MRI substudy, and had contrast-enhanced MR images of the non-dominant hand at months 0, 6, 12, and 24. MR images were evaluated for osteitis, synovitis, tenosynovitis, bone erosion, and joint space narrowing (JSN), using validated scoring methods.Results: Significant reductions were seen at 6months in all inflammatory parameters [synovitis, mean change -1.6 (p

AB - Objectives: To investigate whether a treat-to-target strategy based on methotrexate (MTX) and intra-articular (IA) betamethasone suppresses magnetic resonance imaging (MRI)-determined measures of disease activity and reduces joint destruction in early rheumatoid arthritis (eRA) patients, and to investigate whether concomitant cyclosporin A (CyA) provides an additional effect.Method: In the 2-year randomized, double-blind, treat-to-target trial CIMESTRA, 160 patients with eRA (<6months) were randomized to MTX, intra-articular betamethasone and CyA, or placebo CyA. A total of 129 patients participated in the MRI substudy, and had contrast-enhanced MR images of the non-dominant hand at months 0, 6, 12, and 24. MR images were evaluated for osteitis, synovitis, tenosynovitis, bone erosion, and joint space narrowing (JSN), using validated scoring methods.Results: Significant reductions were seen at 6months in all inflammatory parameters [synovitis, mean change -1.6 (p

U2 - 10.1080/03009742.2016.1209550

DO - 10.1080/03009742.2016.1209550

M3 - Journal article

C2 - 27775461

SN - 0300-9742

VL - 46

SP - 335

EP - 345

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - 5

ER -

Møller-Bisgaard S, Ejbjerg BJ, Eshed I, Hørslev-Petersen K, Hetland ML, Jurik AG et al. Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). Scandinavian Journal of Rheumatology. 2017;46(5):335-345. doi: 10.1080/03009742.2016.1209550